Lupin To Use Honeywell’s Solstice Air Technology For Next-Gen Inhalers

Lupin Ltd said on Tuesday it plans to use Honeywell International Inc.’s Solstice Air technology to develop next-generation inhalers, aiming to transform its respiratory care products. The deal is still under negotiation, with final documents yet to be agreed by both companies.

Financial details were not disclosed in the exchange filing.

Honeywell’s Solstice Air is designed for patients with asthma and chronic obstructive pulmonary disease. It can prevent the release of molecules with high global warming potential, helping to reduce carbon emissions, Lupin explained.

As a leading player in the respiratory segment, Lupin will be the first company to deploy this technology for manufacturing metered-dose inhalers.